![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, July 15, 2022 6:37:16 PM
I believe we will start a major marketing push in q4 to tell the world what we have.
But, in fact, that may not be necessary. The clinical data themselves will spontaneously tell the then-validated Anavex story.
All of the “deficiencies” in previous blarcamesine clinical studies and results will be missing. First, this Alzheimer’s study was big, not thirty or forty participants; big enough that data are statistically reliable and valid. Previous Phase 1 and 2 studies could be dismissed as non-predictive; not enough participants; and, perhaps, not long enough. This trial is big (large N) participant number, and lengthy; long enough that results can’t be by mere happenstance.
And that will all be revealed by the P-values. In conventional, accepted biostatistics, to be valid (and accepted), results mustn’t have a greater chance of mere happenstance, chance results of any greater than 5%, one in twenty. The P-value must be 0.05 or less. Any results larger than 0.05 will disqualify whatever is being measured.
So, what if all of the P-values are <0.05? Simply, then, blarcamesine works; is a viable, useful Alzheimer’s disease therapeutic. No more questions, other than when and how can Alzheimer’s patients start their Anavex therapies?
Unlike Aduhelm, with its untoward brain swelling as a major “adverse event,” side effect, blarcamesine has never, in any of its clinical studies, whether in murines (lab rodents) or real humans, produced adverse events (AEs) of any debilitating consequence. The drug is profoundly safe; uncommon in drugs acting in the central nervous system. The clinical results will not reveal any disqualifying AEs.
So, what results can be problematic for Anavex? Only where symptoms have failed to be controlled, slowed or reversed, by blarcamesine. If blarcamesine is a failure, patients with Alzheimer’s taking it will, over the lengthy treatment period fail to show any improvements. That’s why big clinical studies must have two “arms,” test groups. About half of the study participants will have taken what they think is the drug, blarcamesine. The other half, too, will take what they think is the drug. But the study is “blinded.” The people actually taking the drug, in the “experimental arm,” will get the real drug. The other group, in the “placebo arm,” will take pills that look exactly like the real drug. But those pills will be primarily colored starch, the placebos. No one knows whose taking what until after the trial is completed (just recently). Then, computer coding will unblind the results, the two trial populations will have their results compared.
And that’s what will make big articles in major papers. “New Drug Shows Safe Efficacy Against Alzheimer’s.” Nothing more need be said. Every Alzheimer’s stakeholder, doctors, patients, care-givers, health insurance companies, etc. will scrutinize and devour the outcomes from the study. All of the articulated Anavex naysaying encountered on this stock investment message board in the last seven years will quietly fade into destined oblivion. Press releases from Anavex Life Sciences Corp will be fine. But even without them, the blarcamesine story will be globally validated. A new era in Alzheimer’s therapy, understood by all.
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM